Preeclampsia Drugs Market Analysis 2025–2029: Growth Forecast and Competitive Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the preeclampsia drugs market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Preeclampsia Drugs Market Be Worth By 2029, And What CAGR Will It Achieve?

The preeclampsia drugs market has shown substantial growth in recent years. This market is projected to expand from $1.25 billion in 2024 to $1.37 billion by 2025, reflecting a compound annual growth rate (CAGR) of 9.6%. Historically, this growth has been driven by increased awareness regarding maternal health, progress in research and development, growing concerns over neonatal health, and more effective early detection.

The preeclampsia drugs market size is projected for substantial expansion in the coming years. This market is anticipated to reach $2.1 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.2%. This anticipated growth is primarily driven by advancements such as personalized medicine, the development of non-invasive diagnostic tools, more targeted therapies, and various health equity initiatives. Key trends emerging within this period encompass preventive strategies, a focus on patient-centered care, continuous monitoring solutions, and increased regulatory attention.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Which Factors Are Driving The Preeclampsia Drugs Market Forward?

The increasing incidence of diabetes among expectant mothers is projected to fuel the expansion of the preeclampsia drug market moving forward. Diabetes is a chronic metabolic ailment characterized by elevated blood glucose levels. Preeclampsia is a serious pregnancy complication marked by high blood pressure and organ damage. Metformin, a preeclampsia medication, is extensively utilized in pregnant women facing preterm preeclampsia. For instance, in December 2022, according to the National Library of Medicine, a US-based biomedical library and center of biomedical informatics, the total occurrence of gestational diabetes mellitus (GDM) was 20,865 cases, representing a 6.56% increase in 2022. Therefore, the escalating number of diabetes cases among pregnant women will propel the preeclampsia drug market.

Which Segments Form The Key Structure Of The Preeclampsia Drugs Market?

The preeclampsia drugs market covered in this report is segmented –

1) By Type: Mild Preeclampsia, Severe Preeclampsia

2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications

2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management

What Strategic Shifts And Innovations Are Influencing The Preeclampsia Drugs Market?

Leading firms within the preeclampsia medicine market are prioritizing the creation of advanced drug therapies to enhance their standing in the industry. As an illustration, during March 2023, Comanche Biopharma Corp., a biopharmaceutical company located in the US, announced the Food and Drug Administration (FDA)’s approval of an investigational new drug (IND) application for CBP-4888, Comanche’s distinctive siRNA therapy designed for preeclampsia. CBP-4888 functions as a subcutaneously administered siRNA treatment, which works by decreasing the production of soluble fms-like tyrosine kinase-1 (sFLT1) within the placenta. The main cause of preeclampsia is the placenta’s excessive generation of the protein sFLT1, which subsequently enters the maternal bloodstream. CBP-4888 has the potential to mitigate preeclampsia symptoms, including elevated blood pressure and harm to organs, and could facilitate a safe prolongation of pregnancy.

Which Firms Are Making The Biggest Impact In The Preeclampsia Drugs Market?

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Which Region Is Expected To Lead The Preeclampsia Drugs Market In The Next Few Years?

North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=13025&type=smp

Browse Through More Reports Similar to the Global Preeclampsia Drugs Market 2025, By The Business Research Company

Female Fertility And Pregnancy Rapid Test Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/female-fertility-and-pregnancy-rapid-test-global-market-report

Fertility Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Fertility Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fertility-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795